Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Consun Pharmaceutical Group Ltd. ( (HK:1681) ) has issued an update.
Consun Pharmaceutical Group Ltd. announced the redesignation of Professor Zhu Quan from an executive director to a non-executive director, effective September 25, 2025. This change allows Professor Zhu to focus more on other commitments while continuing to contribute to the company’s research and development efforts. The redesignation is part of the company’s ongoing efforts to optimize its leadership structure and maintain its competitive edge in the pharmaceutical industry.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$22.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the research, development, and production of traditional Chinese medicine and other pharmaceutical products. The company is known for its commitment to advancing medical science and providing quality healthcare solutions.
Average Trading Volume: 3,493,973
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.81B
See more data about 1681 stock on TipRanks’ Stock Analysis page.